Bank of Montreal Can purchased a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 6,209 shares of the company’s stock, valued at approximately $372,000.
A number of other institutional investors also recently added to or reduced their stakes in the business. BlackRock Inc. boosted its position in Prestige Consumer Healthcare by 12.4% during the 1st quarter. BlackRock Inc. now owns 9,115,718 shares of the company’s stock worth $482,584,000 after acquiring an additional 1,004,337 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 0.6% in the third quarter. Vanguard Group Inc. now owns 5,647,622 shares of the company’s stock valued at $281,421,000 after buying an additional 32,646 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Prestige Consumer Healthcare by 0.4% in the first quarter. Dimensional Fund Advisors LP now owns 3,448,246 shares of the company’s stock valued at $182,552,000 after buying an additional 12,790 shares during the period. Macquarie Group Ltd. lifted its holdings in shares of Prestige Consumer Healthcare by 39.6% in the first quarter. Macquarie Group Ltd. now owns 2,753,431 shares of the company’s stock valued at $172,447,000 after buying an additional 781,431 shares during the period. Finally, State Street Corp lifted its holdings in shares of Prestige Consumer Healthcare by 1.2% in the third quarter. State Street Corp now owns 1,944,342 shares of the company’s stock valued at $96,887,000 after buying an additional 22,886 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on PBH. TheStreet lowered Prestige Consumer Healthcare from a “b” rating to a “c+” rating in a report on Thursday, September 7th. StockNews.com lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Royal Bank of Canada cut their target price on Prestige Consumer Healthcare from $110.00 to $103.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 15th. Finally, BMO Capital Markets cut their target price on Prestige Consumer Healthcare from $124.00 to $117.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 15th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Moderate Buy” and a consensus price target of $97.00.
Insider Activity at Prestige Consumer Healthcare
In related news, SVP Mary Beth Fritz sold 2,540 shares of the company’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $58.92, for a total transaction of $149,656.80. Following the transaction, the senior vice president now directly owns 15,934 shares of the company’s stock, valued at $938,831.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.60% of the stock is owned by insiders.
Prestige Consumer Healthcare Stock Down 1.1 %
NYSE:PBH opened at $58.31 on Monday. The firm has a market capitalization of $2.89 billion, a price-to-earnings ratio of -35.13, a PEG ratio of 1.71 and a beta of 0.57. Prestige Consumer Healthcare Inc. has a 1-year low of $55.96 and a 1-year high of $68.54. The company has a current ratio of 2.99, a quick ratio of 1.75 and a debt-to-equity ratio of 0.82. The business’s fifty day moving average price is $58.82 and its 200 day moving average price is $59.48.
About Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
- Five stocks we like better than Prestige Consumer Healthcare
- How to Invest in Blockchain Stocks Step by Step
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- What Does a Stock Split Mean?
- MarketBeat Week in Review – 11/13 – 11/17
- The How and Why of Investing in Biotech Stocks
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.